Targeting Mutant KRAS in Pancreatic Cancer: Futile or Promising?

摘要: Pancreatic ductal adenocarcinoma (PDAC) is one of the most fatal cancers with a dismal prognosis for patient. This due to limited diagnostic options early detection disease as well its rather aggressive nature. Despite major advances in oncologic research general, treatment clinic PDAC have only undergone minor changes last decades. One advance would be successful targeting oncogenic driver KRASmut. In past, indirect KRAS has been exploited, e. g., via upstream inhibition receptor tyrosine kinases or downstream MEK PI3K inhibition. However, experience gained from clinical trials and itself KRASmut cancer entities dampened initial euphoria. Lately, development KRASG12C-specific inhibitors, not direct but also momentum again. Though preclinical studies preliminary monotherapies shown promising results, they overshadowed by swift resistances resulting inconsistent responses patient cohorts. Currently, several different combination therapies are being explored. If hold promise made studies, might suitable patients suffering PDAC.